ISTH Academy

Create Account Sign In
January 17, 2023 | New Era of Management for Thrombotic Microangiopathies
  • 16:00-17:00 UTC (Universal)
  • 11:00-12:00 ET (US & Canada)
  • 17:00-18:00 CET (Central Europe)
  • Jan 18 | 0:00-1:00 HKT (Asia Pacific)

EVENT OUTLINE

  • Introduction by Senthil Sukumar, M.D.
  • Treatment of Thrombotic Microangiopathies by Spero Cataland, M.D. (20 minutes)
  • Etiology-based Differential Diagnosis of TMA by Johanna Kremer Hovinga, M.D. (20 minutes)
  • Q&A with audience (15 minutes)

This webinar is supported by Werfen

Speakers

MODERATOR

Senthil Sukumar, M.D.
Baylor College of Medicine
Houston, Texas, United States

 

SPEAKERS

Johanna Kremer Hovinga, M.D.
Bern University Hospital
University of Bern
Bern, Switzerland

 

Spero Cataland, M.D.
Ohio State University
Columbus, Ohio, United States

Explore a new CME module on cTTP: Protecting Patients, Today and Tomorrow!
  • Upon completion of this activity, the learners should be able to:
  • Identify common challenges for patients with cTTP, including the high disease burden during acute episodes, sub-acute manifestations, and long-term organ damage
  • Assess limitations of current plasma-based standard of care therapy for patients with cTTP
  • Develop prophylactic treatment strategies for cTTP to avoid sub-acute manifestations and long- term organ damage
  • Associate emerging cTTP therapies with their potential clinical effects on acute episodes as well as post-acute disease stages

Accreditation Type: AMA PRA Category 1 Credit(s)™

Activity Dates: December 23,  2022— December 23, 2023

Estimated Time to Complete Activity: 60 Minutes

 

TARGET AUDIENCE
This educational activity is intended for physicians, advanced practice professionals (APPs), nurse practitioners, PAs who specialize in hematology, and other members of the health care team who care for patients with cTTP. 

PROGRAM OVERVIEW
This self-guided, case-based educational activity reviews the high burden of disease and its treatment, the risk of relapse and long-term complications, and the emerging treatment approaches under investigation for cTTP.  

 

 

The France Foundation and ISTH present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, ISTH, and the commercial supporter(s) assume no liability for the information herein.

 

This activity is supported by an educational grant from Takeda.

FACULTY

Spero R. Cataland, MD
Professor of Internal Medicine, Division of Hematology
Ohio State University

Shruti Chaturvedi, MD
Associate Professor of Medicine
Johns Hopkins

Katerina Pavenski, MD
Head, Division Transfusion Medicine
St. Michael’s Hospital
Associate Professor, Departments of Medicine and Laboratory Medicine
University of Toronto

December 7 , 2022 | Anti-fibrinolytic Therapy: Do's and Don'ts
  • 18:40-19:40 UTC (Universal)
  • 13:40-14:40 ET (US & Canada)
  • 19:40-20:40 CET (Central Europe)
  • December 8 | 2:40-3:40 HKT (Asia Pacific)

EVENT OUTLINE

  • Introduction by Tetsumei Urano, M.D., Ph.D.
  • Tranexamic Acid: A Vaccine to Prevent Life Threatening Bleeding by Ian Roberts (20 min)
  • Anti-fibrinolytic Therapy: Don'ts by Michelle Sholzberg, M.D. (20 min)
  • Q&A with audience (15 min)

Moderator

Tetsumei Urano, M.D., Ph.D.
Shizuoka Graduate University of Public Health
Hamamatsu University School of Medicine
Shizuoka, Japan

 

Speakers

Ian Roberts
London School of Hygiene & Tropical Medicine
London, England, United Kingdom

 

Michelle Sholzberg, M.D.
Coagulation Laboratory at St. Michael's Hospital
Li Ka Shing Knowledge Institute
Toronto, Ontario, Canada

Learning Objectives | Upon completion of the activity, participants should be able to:
  • Discuss treatment considerations for persistent/chronic ITP
  • Evaluate the clinical information of approved and emerging therapies for persistent/chronic ITP
  • Develop individualized treatment strategies for patients with persistent/chronic ITP

TARGET AUDIENCE
The primary target audience for this content is physicians, nurse practitioners, nurses and other members of the hematology care team.

STATEMENT OF NEED
Clinicians may not know the best options for treating patients with persistent/chronic ITP who need treatment, including modifications beyond the acute ITP phase. These patients may also require individualization of treatment approach based on patient and disease characteristics.

METHOD OF PARTICIPATION/ HOW TO RECEIVE CREDIT:

  1. There are no fees for participating in and receiving credit for this activity
  2. Review the activity objectives and CME/CE information
  3. Complete the CME/CE activity
  4. Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Complete the CME/CE evaluation/attestation form. This form provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  6. Your CME/CE certificate will be available for download

 

DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and International Society on Thrombosis and Haemostasis (ISTH) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ISTH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ISTH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ISTH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

ACTIVITY STAFF DISCLOSURES
Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships:

  • Cindy Neunert, MD has research funding from Novartis
  • Hanny Al-Samkari, MD is a consultant for Agios, Dova/Sobi, Forma, Novartis, Moderna, argenx, and Rigel and has research funding for Agios, Dova/Sobi, and Amgen
  • Adam Cuker, MD is a consultant and has authoring royalties for Synergy CRO and the New York Blood Center

COMMERCIAL SUPPORT ACKNOWLEDGEMENT

This activity is supported by educational grants from Novartis, UCB, argenx, and Amgen.

FACULTY

 

Cindy Neunert, MD, MSCS (Chair)
Section Head, Pediatric Hematology
Columbia University Medical Center
New York, NY

Adam Cuker, MD, MS
Director, Penn Comprehensive and Hemophilia Thrombosis Program
Clinical Director, Penn Blood Disorders Center
Section Chief, Benign Hematology
Associate Professor of Medicine, University of Pennsylvania
Associate Professor of Pathology and Laboratory Medicine
Philadelphia, PA

Hanny Al-Samkari, MD
Classical Hematologist and Clinical Investigator
Co-director, Hereditary Hemorrhagic Telangiectasia Center
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

November 8, 2022 | Traumatic Brain Injury Associated Coagulopathy: Theory and Practice
  • 17:00-18:00 UTC (Universal)
  • 12:00-13:00 EST (US & Canada)
  • 19:00-20:00 CEST (Central Europe)
  • November 9 | 1:00-2:00 HKT (Asia Pacific)

EVENT OUTLINE

  • Introduction by Sam Neuffer, Ph.D.
  • Mouse Models of Traumatic Brain Injury-induced Coagulopathy by Jing-fei Dong, M.D., Ph.D. (20 min)
  • TBI-associated Coagulopathy: Clinical Diagnosis and Management by Marc Maegele, M.D. (20 min)
  • Q&A with audience (15 min)

This webinar is supported by Werfen

 

 

 

 

 

Faculty

Moderator

Sam Neuffer, Ph.D.
Bloodworks Research Institute 
Seattle, Washington, USA

 

Speakers

Jing-fei Dong, M.D., Ph.D.
Bloodworks Research Institute
Division of Hematology
University of Washington School of Medicine
Seattle, Washington, USA

 

Marc Maegele, M.D.
Department of Trauma/Orthopedic Surgery
University of Witten/Herdecke
Department of Experimental Research
University of Witten/Herdecke Institute for Research in Operative Medicine
Cologne, Germany

EARLY CAREER WEBINAR: NOVEMBER 2, 2022 | Science and Social Media: How to Communicate to a Wider Audience
  • 16:30 UTC (Universal)
  • 12:30 EDT (US & Canada)
  • 18:30 CEST (Central Europe)
  • November 3 | 0:30 HKT (Asia Pacific)

Learning Objectives: 

  • Appraise the value of various platforms for free, modular education
  • To understand which platform works for you and your SciComm
  • How to get started with SciComm online and tackle nerves when putting yourself out there online
  • How to build your brand and niche
  • How social media / Twitter can be utilized as a novel tool to educate and help advance your research career
We found no results for your search. Please change or remove at least one filter to broaden your search.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies